. Author manuscript; available in PMC: 2011 Jul 9.

Published in final edited form as: Int J Cardiol. 2010 Mar 19;150(1):17–21. doi: 10.1016/j.ijcard.2010.02.021

Table 3.

Adjusted associations of lipoprotein(a) with coronary calcification in (A) non-diabetic and (B) diabetic subjects.

Model adjusted for	Men	Women
Model adjusted for	Tobit Ratio (95% CI)	Tobit Ratio (95% CI)
(A) Non-diabetic subjects
Age and race	1.02 (0.85–1.23), p=0.85	1.12 (0.86–1.45), p=0.41
Age, race, meds, exercise, FRS, Metsyn, and CRP	1.10 (0.91–1.32), p=0.33	1.11 (0.87–1.43), p=0.40
(B) Type-2 diabetic subjects
Age and race	0.97 (0.78–1.21), p=0.77	2.76 (1.73–4.40), p<0.001
Age, race, meds, exercise, FRS, Metsyn, and CRP	0.88 (0.67–1.14), p=0.32	2.40 (1.41–4.07), p<0.001
Age, race, meds, exercise, FRS, Metsyn, CRP, BMI, and HbA1c	0.90 (0.69–1.17), p=0.42	2.25 (1.34–3.79), p=0.002

Results of Tobit regression are presented as the ratio of increase in coronary artery calcification score for a natural log fold increase in Lp(a) levels. Metsyn=Metabolic Syndrome, Meds include aspirin, statin, niacin and ace inhibitor use, FRS=Framingham Risk Score, BMI=body mass index.